While M&A activity slowed in the first quarter of 2025,
including in life sciences, there have been plenty of noteworthy
developments in the antitrust space in the first 100 days of the
Trump administration. The Federal Trade Commission (FTC) under new
Chairman Andrew Ferguson has already launched its first merger
challenge while also signaling a more deal-friendly approach by
reinstituting the "early termination" process, whereby
the FTC uses its discretion to terminate a Hart-Scott-Rodino (HSR)
review prior to the expiration of the statutory review period in
instances in which the transaction does not present any competitive
issues.
Whether or not it is indicative of a more permissive approach to
life sciences merger enforcement, the obesity therapeutics space
remains a hotbed of M&A activity. While a variety of players
have aggressively expanded their weight-loss drug portfolios
through acquisitions, licensing agreements, and partnerships, these
deals have thus